SynthesisChronic respiratory disease2017
Managing fatigue in sarcoidosis - A systematic review of the evidence.
Synthesis in Chronic respiratory disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 39 citations in OpenAlex.
- Feasibility of investigating methylphenidate for the treatment of sarcoidosis-associated fatigue (the FaST-MP study): a double-blind, parallel-arm randomised feasibility trial.BMJ open respiratory research · 2021Trial
- Trial
- Effects of yoga-based and conventional physiotherapy programs on functional, respiratory, and psychosocial outcomes in stage II sarcoidosis: A randomized controlled trial.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026Article
- Advances in management of sarcoidosis-associated fatigue: A narrative review.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026Article
- Contemporary management of sarcoidosis.Frontiers in medicine · 2026Review
- Like walking through treacle: the experience of fatigue for young people with interstitial lung disease.Orphanet journal of rare diseases · 2025Article
- Article
- Validity and Reliability of the Fatigue Severity Scale in a Real-World Interstitial Lung Disease Cohort.American journal of respiratory and critical care medicine · 2023Article
- Design and rationale of a pilot randomized clinical trial investigating the use of a mHealth app for sarcoidosis-associated fatigue.Contemporary clinical trials communications · 2023Article
- Treat to target and tight control: Could be a new approach in the treatment of sarcoidosis?Intractable & rare diseases research · 2023Review
- Perceptions of the Fatigue Experience and a Breathing Awareness Meditation-Integrated mHealth App for Fatigue and Stress in Patients with Sarcoidosis.Fatigue : biomedicine, health & behavior · 2023Article
- Safety of corticosteroid therapy in sarcoidosis treatment.Frontiers in drug safety and regulation · 2023Review
- Prevalence and characteristics of self-reported hypothyroidism and its association with nonorgan-specific manifestations in US sarcoidosis patients: a nationwide registry study.ERJ open research · 2021Article
- Erythropoietin Mimetic Peptide (pHBSP) Corrects Endothelial Dysfunction in a Rat Model of Preeclampsia.International journal of molecular sciences · 2020Article
- Severe Fatigue is Highly Prevalent in Patients with IPF or Sarcoidosis.Journal of clinical medicine · 2020Article
- The effects of High- versus Moderate-Intensity Exercise on Fatigue in Sarcoidosis.Journal of clinical medicine · 2019Article
- First patient-centred set of outcomes for pulmonary sarcoidosis: a multicentre initiative.BMJ open respiratory research · 2019Article
- Fatigue, Sleep, and Autoimmune and Related Disorders.Frontiers in immunology · 2019Review
- Sarcoid of the Upper Humerus Found Incidentally on MR Images Obtained for Work-Up of Rotator Cuff Tear Where Compromised Tissue Quality Was a Concern for Surgical Success.Case reports in radiology · 2018Article
- Fatigue interventions in long term, physical health conditions: A scoping review of systematic reviews.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Fatigue is a common manifestation of sarcoidosis, often persisting without evidence of disease activity. First-line therapies for sarcoidosis have limited effect on fatigue. This review aimed to assess the treatment options targeting sarcoidosis-associated fatigue. Medline and Web of Science were searched in November 2015; the bibliographies of these papers, and relevant review papers, were also searched. Studies were included if they reported on the efficacy of interventions (both pharmacological and non-pharmacological) on fatigue scores in sarcoidosis patients. Eight studies were identified that fulfilled the inclusion criteria. These studies evaluated six different interventions (infliximab, adalimumab, ARA 290, methylphenidate, armodafinil and exercise programmes). There is evidence to support a treatment effect of anti-tumour necrosis factor (TNF)-αtherapies (adalimumab and infliximab) and neurostimulants (methylphenidate and armodafinil), but within five of the studies, the risk of bias was high within most domains and the remaining three studies included only small numbers of participants and were short in duration. Trial evidence for treating fatigue as a manifestation of sarcoidosis is limited and requires further investigation. Anti-TNF-α therapies may be beneficial in patients with organ-threatening disease. Neurostimulants have some trial evidence supporting improvements in fatigue but further investigation is needed before they can be recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.